Does Mounjaro lower blood sugar — and how does that work?

Step 1, two receptors fire at once

Most GLP-1 medicines work on a single receptor. Tirzepatide targets two: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Both are part of the gut-hormone system that tells the pancreas how to respond to food. Activating them together produces a more pronounced insulin response than either would alone, which is the core reason tirzepatide's blood-sugar reduction is stronger than that seen with older GLP-1-only medicines in head-to-head trials.

The NHS's tirzepatide medicines page explains this dual mechanism clearly and is worth reading if you want the patient-level summary. For a deeper clinical overview, the tirzepatide overview at nume covers what the trials showed across different patient groups.

Step 2, glucose-dependent insulin release keeps hypoglycaemia risk low

A concern with some diabetes medicines is that they drive insulin release regardless of what blood sugar is doing, which can push levels too low. Tirzepatide does not do this. The extra insulin it stimulates is glucose-dependent: the signal only fires when circulating glucose is genuinely elevated. Once levels normalise, the stimulus fades. That's why hypoglycaemia is uncommon with tirzepatide on its own, though if you want to understand the specific circumstances where it can occur, our page on Mounjaro and low blood sugar covers the risk factors and what to watch for, and the risk rises further if it is combined with insulin or a sulphonylurea, your prescriber will account for this.

This mechanism is described in the BNF entry for tirzepatide, which sets out the clinical pharmacology and interaction considerations that guide prescribing decisions in the UK.

Step 3, gastric emptying slows, blunting the post-meal spike

Beyond the direct insulin effect, tirzepatide slows the rate at which the stomach empties into the small intestine. Food arrives more gradually, so glucose from a meal enters the bloodstream more slowly too. The sharp post-meal spikes that drive a lot of daily glucose variability are flattened. For people with type 2 diabetes, this is clinically meaningful. For people taking Mounjaro for weight management, it also contributes to earlier satiety and reduced appetite, the same physiology does both jobs at once.

Gastric slowing can be relevant if you take other oral medicines, since absorption timing may shift. Our prescribers review your full medication list at consultation, and more detail on how Mounjaro's effects interact with other conditions is covered on our page about how Mounjaro affects blood sugar.

What this means in practice, and when it matters

For people with type 2 diabetes, the blood-sugar-lowering effect is the primary therapeutic aim. If you are wondering whether this applies to you, our page on whether Mounjaro reduces blood sugar explains how the effect plays out across different patient groups, including those with prediabetes and insulin resistance. The SURMOUNT-2 trial (published in The Lancet) studied tirzepatide specifically in adults with obesity and type 2 diabetes, finding clinically significant HbA1c reductions alongside substantial weight loss. For people without diabetes who are using Mounjaro for weight management, blood-sugar reduction is a secondary benefit rather than the target, meaningful for those with prediabetes or insulin resistance, but monitored rather than optimised.

If you are already on diabetes medication when you start Mounjaro, your prescriber may need to adjust your other medicines as glucose levels improve. Stopping or reducing insulin or sulphonylureas too abruptly carries risk; this is managed as part of ongoing clinical review, not something to do independently. If you are curious about the cost side of treatment, our Mounjaro price comparison guide sets out what private prescriptions typically include so you can assess value fairly. For questions about related effects, the page on whether Mounjaro lowers blood pressure covers a separate but often-asked cardiovascular question. Everything that matters about your individual suitability is assessed by a real prescriber at your free consultation, not a form that auto-approves.

Our clinical team's approach to reviewing these dual-indication cases is outlined on the clinical team page if you want to understand who is making these decisions.